Compare Gilead Sciences, Inc. (GILD) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while JPMorgan Diversified Return International Eqty ETF trades at $77. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while JPMorgan Diversified Return International Eqty ETF pays none, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | JPIN | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | — |
52-Week High | $155.80 | $77.00 |
52-Week Low | $110.56 | $64.96 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
JPIN trades at $76.515, up 0.2% today, with technical indicators signaling a bullish trend from moving averages but caution from overbought RSI levels. The ETF, launched in 2014, provides exposure to foreign large-cap value stocks, with a dividend scheduled for June 2026. Recent news highlights its smart beta strategy and broad market category focus.
The outlook remains positive due to strong technical momentum and diversified international equity exposure, though overbought conditions and reliance on global markets pose risks. Investors benefit from value-oriented strategies but should monitor international economic volatility for potential impacts on performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
